Company: SCLXW
Filing Date: 2025-02-14
Form Type: PRE 14A
Source: 0001193125-25-027244
Chunk: 39

Company: Scilex Holding Co
Filing Date: 2025-02-14
Form: PRE 14A
Chunk 39
---
 days of January 31, 2025 and 2,300 
 shares held directly.                                                                                 |

| (7) | Represents 36,457 shares subject to options exercisable within 60 days of January 31, 2025. |

| (8) | Represents 505,139 shares subject to options exercisable within 60 days of January 31, 2025 and 25,000 
 shares held directly.                                                                                  |

| (9) | Represents (a) 51,039,214 shares of Common Stock held directly and (b) 490,617 shares underlying SPAC                                                                                                                                                                                                                                   
 Warrants (as defined in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 12, 2024 (the “Form 10-K”)), all of which are currently exercisable, in each case, transferred to SCLX JV in connection with the Equity Repurchase Transaction (as defined in the Form 10-K). 
 Does not include any shares of Series A Preferred Stock. The voting and dispositive power of the equity securities of the Company (including the Series A Preferred Stock) held by SCLX JV are subject to the control of an independent manager, Jack Wu,                                                                               
 until such time as the Oramed Note and any Additional Notes (each as defined in the Form 10-K) are paid in full. The business address of SCLX Stock Acquisition JV LLC is 960 San Antonio Road, Palo Alto, CA                                                                                                                           
 94303.                                                                                                                                                                                                                                                                                                                                  |

| (10) | The ownership information for Oramed Pharmaceuticals Inc. (“Oramed”) is based on information                                                                                                                                                           
 supplied by Oramed in a statement on Schedule 13G filed with the SEC on January 17, 2025, reporting that Oramed had sole voting power with respect to 15,500,000 shares of Common Stock, sole dispositive power with respect to 15,500,000             
 shares of Common Stock, and beneficial ownership of an aggregate of 15,500,000 shares of Common Stock, in each case, comprised of (a) 9,000,000 shares of Common Stock held directly and (b) 6,500,000 shares underlying penny warrants held by Oramed 
 exercisable within 60 days of January 31, 2025. The business address of Oramed Pharmaceuticals Inc. is 1185 Avenue